Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zidovudine

R Sperling1

  • 1Department of Obstetrics, Gynecology, and Reproductive Sciences, Mount Sinai Medical Center, New York, NY 10029-6574, USA. rsperling@smtplink.mssm.edu

Infectious Diseases in Obstetrics and Gynecology
|January 23, 1999
PubMed
Summary
This summary is machine-generated.

Zidovudine (ZDV) is a key HIV treatment and the only FDA-approved drug for preventing mother-to-child HIV transmission. Current research focuses on optimizing ZDV therapy timing for maximum effectiveness in preventing HIV transmission.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2025
Same author

The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.

The journal of prevention of Alzheimer's disease·2024
Same author

Editorial: Introduction to the Special Issue on the A4 Study.

The journal of prevention of Alzheimer's disease·2024
Same author

Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4.

The journal of prevention of Alzheimer's disease·2024
Same author

Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial.

The journal of prevention of Alzheimer's disease·2024
Same author

Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report.

The journal of prevention of Alzheimer's disease·2022
Same journal

Intrapartum and 30-Day Postpartum Complications in Patients With Antenatal COVID-19 Infection: A Retrospective Cohort Study.

Infectious diseases in obstetrics and gynecology·2024
Same journal

CER818: A Highly Specific and Sensitive HPV L1 High-Risk Serological Lateral Flow Rapid Test for Early Detection of Cervical Cancer and Its Precursor Lesions.

Infectious diseases in obstetrics and gynecology·2024
Same journal

Determinants of Cervical Cancer Screening among Female Health Professionals in Harar Town, Eastern Ethiopia: A Cross-Sectional Study.

Infectious diseases in obstetrics and gynecology·2024
Same journal

Seroinfection of Antibodies to <i>Toxoplasma gondii</i>, Parvovirus B19, <i>Treponema pallidum</i>, and HIV in a Pregnant Attending a Medical Center in Northern Peru.

Infectious diseases in obstetrics and gynecology·2024
Same journal

Seroprevalence of <i>Toxocara</i> spp. in Pregnant Women: A Systematic Review and Meta-Analysis.

Infectious diseases in obstetrics and gynecology·2024
Same journal

Risk Factors Associated with Congenital Syphilis, Georgia, 2008-2015.

Infectious diseases in obstetrics and gynecology·2023
See all related articles

Area of Science:

  • Antiviral therapy
  • Pharmacokinetics
  • HIV/AIDS research

Background:

  • Zidovudine (ZDV) was the first approved HIV treatment.
  • ZDV is used in combination therapy for adult and pediatric HIV-1 infection.
  • ZDV is the sole FDA-approved agent for preventing mother-to-child HIV-1 transmission.

Purpose of the Study:

  • To evaluate the effectiveness of Zidovudine (ZDV) in preventing mother-to-child HIV-1 transmission.
  • To determine the optimal timing for initiating ZDV therapy during gestation.
  • To assess the importance of intrapartum and newborn ZDV components.

Main Methods:

  • Review of existing studies on ZDV effectiveness.
  • Analysis of interventional and observational studies on ZDV timing.

Related Experiment Videos

  • Evaluation of the ACTG 076 regimen.

    • Main Results:

    • ZDV effectiveness in preventing mother-to-child HIV-1 transmission is established.
    • Optimal ZDV initiation time and component importance are under investigation.
    • The combined maternal/newborn ZDV regimen from ACTG 076 is the current US standard.

    Conclusions:

    • Zidovudine (ZDV) plays a critical role in HIV treatment and prevention.
    • Further research is ongoing to optimize ZDV regimens for preventing mother-to-child HIV transmission.
    • The ACTG 076 regimen remains the recommended approach in the US pending new trial data.